Reata clinical trials
Acquired by Biogen, Sep 26, 2023 · source ↗
The registry lists 1 studies whose lead sponsor is Reata. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Dec 15, 2025.
Before and after it joined Biogen
- First submitted before Reata became part of Biogen
- 1
- First submitted after Reata became part of Biogen
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Reata, a wholly owned subsidiary of Biogen1 study
Something wrong with this grouping? Tell us on the Biogen page.
Studies
Recruiting first, then most recently updated. Showing 1 of 1. All Biogen studies →
- A Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic PainTerminatedNCT05895552Phase 2
Sponsor listed in the registry: Reata, a wholly owned subsidiary of Biogen · First submitted before Reata became part of Biogen